Advances in Computational Approaches for the Discovery of Therapeutics and Personalized Medicine

A special issue of Biomolecules (ISSN 2218-273X). This special issue belongs to the section "Bioinformatics and Systems Biology".

Deadline for manuscript submissions: closed (30 June 2025) | Viewed by 1231

Special Issue Editor


E-Mail Website
Guest Editor
Department of Molecular Imaging and Therapy, City of Hope National Medical Center, 1500 E Duarte Road, Duarte, CA 91010, USA
Interests: protein folding; dynamics and allostery; protein-protein interaction; small molecule; peptide and aptamer design; method development for drug discovery; multiscale modeling and dynamics

Special Issue Information

Dear Colleagues,

The rational design of synthetic molecules for treating human diseases is a cornerstone of modern medicine. Yet, the diversity and complexity of biological systems, combined with the vastness of chemical space, make designing therapeutic agents challenging. High-throughput computational pipelines can complement experimental screening assays by prioritizing drug candidates or optimizing existing molecules, thereby accelerating bench-to-bedside programs. This Special Issue aims to highlight the cutting-edge advances in computational methods for the discovery of therapeutics, address the challenges faced in the field, and identify untapped potentials for future development.

Research topics of interest include the following:

  • High-throughput virtual screening methods for the target-specific discovery of small molecules.
  • Drug discovery for challenging targets, e.g., transcription factors and intrinsically disordered proteins.
  • Computational approaches for lead optimization.
  • Design of biologics, e.g., monoclonal antibodies, antibody–drug conjugates, PROTACs, aptamers, CAR-T, and gene therapy agents.
  • Design of effective drug delivery agents.
  • Prediction of bioavailability and off-target effects.

We seek to cover both traditional computational methods applying structural biology, molecular force fields, and empirical models, as well as the emerging field of ML/AI-driven approaches. Original research articles and comprehensive reviews that summarize cutting-edge research and the key challenges in this area are welcome. Researchers from both academia and industry are invited to contribute to this Special Issue.

Dr. Supriyo Bhattacharya
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • high-throughput virtual screening
  • CADD
  • machine learning
  • biologics design
  • off-target effect prediction

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

15 pages, 839 KB  
Article
Comparative Evaluation of Mutect2, Strelka2, and FreeBayes for Somatic SNV Detection in Synthetic and Clinical Whole-Exome Sequencing Data
by Igor López-Cade, Alicia Gómez-Sanz, Adrián Sanvicente, Cristina Díaz-Tejeiro, Aránzazu Manzano, Pedro Pérez-Segura, Balázs Győrffy, Alberto Ocaña, Miguel de la Hoya and Vanesa García-Barberán
Biomolecules 2025, 15(11), 1532; https://doi.org/10.3390/biom15111532 - 30 Oct 2025
Viewed by 818
Abstract
Somatic variant calling is a critical step in cancer genome analysis, but the performance of available tools can vary depending on their underlying algorithms and filtering strategies. We compared three widely used variant callers—Mutect2, Strelka2, and FreeBayes—for their performance in somatic single-nucleotide variant [...] Read more.
Somatic variant calling is a critical step in cancer genome analysis, but the performance of available tools can vary depending on their underlying algorithms and filtering strategies. We compared three widely used variant callers—Mutect2, Strelka2, and FreeBayes—for their performance in somatic single-nucleotide variant (SNV) detection using both synthetic and real whole-exome sequencing (WES) data. Synthetic data were generated by introducing 4709 SNVs into a variant-free BAM file, while real data consisted of tumor and matched normal WES samples from five ovarian cancer (OC) patients. All callers were run using the nf-core/sarek pipeline with default settings and appropriate filtering. In the synthetic dataset, all tools showed high precision (~99.9%), with Mutect2 achieving the highest recall (63.1%), followed by Strelka2 (46.3%) and FreeBayes (45.2%). In real samples, FreeBayes detected the most variants, and only 5.1% of SNVs were shared across all three tools. We then integrated calls with SomaticSeq in consensus mode (Mutect2 + Strelka2) and kept variants with stronger allelic signals—showing higher VAFs and, typically, higher coverages relative to single-caller only. Caller-exclusive variants showed significant differences in allele frequency and sequencing depth. These results highlight substantial variability in SNV detection across tools. While all showed high specificity, differences in sensitivity and variant profiles underscore the need for context-specific caller selection or ensemble approaches in cancer genomics. Full article
Show Figures

Graphical abstract

Back to TopTop